Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Review

Can untreated PKU patients escape from intellectual disability? A systematic review

Authors: Danique van Vliet, Annemiek M. J. van Wegberg, Kirsten Ahring, Miroslaw Bik-Multanowski, Nenad Blau, Fatma D. Bulut, Kari Casas, Bozena Didycz, Maja Djordjevic, Antonio Federico, François Feillet, Maria Gizewska, Gwendolyn Gramer, Jozef L. Hertecant, Carla E. M. Hollak, Jens V. Jørgensen, Daniela Karall, Yuval Landau, Vincenzo Leuzzi, Per Mathisen, Kathryn Moseley, Neslihan Ö. Mungan, Francesca Nardecchia, Katrin Õunap, Kimberly K. Powell, Radha Ramachandran, Frank Rutsch, Aria Setoodeh, Maja Stojiljkovic, Fritz K. Trefz, Natalia Usurelu, Callum Wilson, Clara D. van Karnebeek, William B. Hanley, Francjan J. van Spronsen

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Phenylketonuria (PKU) is often considered as the classical example of a genetic disorder in which severe symptoms can nowadays successfully be prevented by early diagnosis and treatment. In contrast, untreated or late-treated PKU is known to result in severe intellectual disability, seizures, and behavioral disturbances. Rarely, however, untreated or late-diagnosed PKU patients with high plasma phenylalanine concentrations have been reported to escape from intellectual disability. The present study aimed to review published cases of such PKU patients.

Methods

To this purpose, we conducted a literature search in PubMed and EMBASE up to 8th of September 2017 to identify cases with 1) PKU diagnosis and start of treatment after 7 years of age; 2) untreated plasma phenylalanine concentrations ≥1200 μmol/l; and 3) IQ ≥80. Literature search, checking reference lists, selection of articles, and extraction of data were performed by two independent researchers.

Results

In total, we identified 59 published cases of patients with late-diagnosed PKU and unexpected favorable outcome who met the inclusion criteria. Although all investigated patients had intellectual functioning within the normal range, at least 19 showed other neurological, psychological, and/or behavioral symptoms.

Conclusions

Based on the present findings, the classical symptomatology of untreated or late-treated PKU may need to be rewritten, not only in the sense that intellectual dysfunction is not obligatory, but also in the sense that intellectual functioning does not (re)present the full picture of brain damage due to high plasma phenylalanine concentrations. Further identification of such patients and additional analyses are necessary to better understand these differences between PKU patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fölling A. Uber Ausscheidung von Phenylbrenztraubensaure in den Harn als Stoff wechselanomalie in Verbindung mit Inbicillitat. Ztschr Physiol Chem. 1934;227:169.CrossRef Fölling A. Uber Ausscheidung von Phenylbrenztraubensaure in den Harn als Stoff wechselanomalie in Verbindung mit Inbicillitat. Ztschr Physiol Chem. 1934;227:169.CrossRef
2.
go back to reference BICKEL H, GERRARD J, HICKMANS EM. Influence of phenylalanine intake on phenylketonuria. Lancet. 1953;265(6790):812–3.CrossRefPubMed BICKEL H, GERRARD J, HICKMANS EM. Influence of phenylalanine intake on phenylketonuria. Lancet. 1953;265(6790):812–3.CrossRefPubMed
3.
go back to reference GUTHRIE R, SUSI A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–43.PubMed GUTHRIE R, SUSI A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–43.PubMed
5.
go back to reference Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams J. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39(3):171–87.CrossRefPubMed Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams J. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39(3):171–87.CrossRefPubMed
6.
go back to reference Jahja R, Huijbregts SCJ, de Sonneville LMJ, van der Meere JJ, Legemaat AM, Bosch AM, Hollak CEM, Rubio-Gozalbo ME, Brouwers MCGJ, Hofstede FC, de Vries MC, Janssen MCH, van der Ploeg AT, Langendonk JG, van Spronsen FJ. Cognitive profile and mental health in adult phenylketonuria: a PKU-COBESO study. Neuropsychology. 2017;31(4):437–47.CrossRefPubMed Jahja R, Huijbregts SCJ, de Sonneville LMJ, van der Meere JJ, Legemaat AM, Bosch AM, Hollak CEM, Rubio-Gozalbo ME, Brouwers MCGJ, Hofstede FC, de Vries MC, Janssen MCH, van der Ploeg AT, Langendonk JG, van Spronsen FJ. Cognitive profile and mental health in adult phenylketonuria: a PKU-COBESO study. Neuropsychology. 2017;31(4):437–47.CrossRefPubMed
7.
go back to reference Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, van Spronsen FJ. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr. 2014;164(4):895–9. e2CrossRefPubMed Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, van Spronsen FJ. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr. 2014;164(4):895–9. e2CrossRefPubMed
8.
go back to reference Jahja R, van Spronsen FJ, de Sonneville LM, van der Meere JJ, Bosch AM, Hollak CE, Rubio-Gozalbo ME, Brouwers MC, Hofstede FC, de Vries MC, Janssen MC, van der Ploeg AT, Langendonk JG, Huijbregts SC. Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study. J Inherit Metab Dis. 2016;39(3):355–62.CrossRefPubMedPubMedCentral Jahja R, van Spronsen FJ, de Sonneville LM, van der Meere JJ, Bosch AM, Hollak CE, Rubio-Gozalbo ME, Brouwers MC, Hofstede FC, de Vries MC, Janssen MC, van der Ploeg AT, Langendonk JG, Huijbregts SC. Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study. J Inherit Metab Dis. 2016;39(3):355–62.CrossRefPubMedPubMedCentral
9.
go back to reference Smith I, Knowles J. Behaviour in early treated phenylketonuria: a systematic review. Eur J Pediatr. 2000;159(Suppl 2):S89–93.CrossRefPubMed Smith I, Knowles J. Behaviour in early treated phenylketonuria: a systematic review. Eur J Pediatr. 2000;159(Suppl 2):S89–93.CrossRefPubMed
10.
go back to reference Hsia DY, O'Flynn ME, Berman JL. Atypical phenylketonuria with borderline or normal intelligence. Am J Dis Child. 1968;116(2):143–57.PubMed Hsia DY, O'Flynn ME, Berman JL. Atypical phenylketonuria with borderline or normal intelligence. Am J Dis Child. 1968;116(2):143–57.PubMed
11.
go back to reference Primrose DA. Phenylketonuria with normal intelligence. J Ment Defic Res. 1983;27(Pt 4):239–46.PubMed Primrose DA. Phenylketonuria with normal intelligence. J Ment Defic Res. 1983;27(Pt 4):239–46.PubMed
12.
go back to reference van Spronsen FJ, van Wegberg AM, Ahring K, Belanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Gizewska M, Huijbregts SC, Kearney S, Leuzzi V, Maillot F, Muntau AC, Trefz FK, van Rijn M, Walter JH, MacDonald A. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–56.CrossRefPubMed van Spronsen FJ, van Wegberg AM, Ahring K, Belanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Gizewska M, Huijbregts SC, Kearney S, Leuzzi V, Maillot F, Muntau AC, Trefz FK, van Rijn M, Walter JH, MacDonald A. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–56.CrossRefPubMed
13.
go back to reference COFFELT RW. Unexpected finding from a Pku newborn screening program. Pediatrics. 1964;34:889–90.PubMed COFFELT RW. Unexpected finding from a Pku newborn screening program. Pediatrics. 1964;34:889–90.PubMed
14.
15.
go back to reference Thompson AJ, Smith I, Brenton D, Youl BD, Rylance G, Davidson DC, Kendall B, Lees AJ. Neurological deterioration in young adults with phenylketonuria. Lancet. 1990;336(8715):602–5.CrossRefPubMed Thompson AJ, Smith I, Brenton D, Youl BD, Rylance G, Davidson DC, Kendall B, Lees AJ. Neurological deterioration in young adults with phenylketonuria. Lancet. 1990;336(8715):602–5.CrossRefPubMed
16.
go back to reference Leuzzi V, Trasimeni G, Gualdi GF, Antonozzi I. Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. J Inherit Metab Dis. 1995;18(5):624–34.CrossRefPubMed Leuzzi V, Trasimeni G, Gualdi GF, Antonozzi I. Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. J Inherit Metab Dis. 1995;18(5):624–34.CrossRefPubMed
17.
go back to reference Kasim S, Moo LR, Zschocke J, Jinnah HA. Phenylketonuria presenting in adulthood as progressive spastic paraparesis with dementia. J Neurol Neurosurg Psychiatry. 2001;71(6):795–7.CrossRefPubMedPubMedCentral Kasim S, Moo LR, Zschocke J, Jinnah HA. Phenylketonuria presenting in adulthood as progressive spastic paraparesis with dementia. J Neurol Neurosurg Psychiatry. 2001;71(6):795–7.CrossRefPubMedPubMedCentral
18.
go back to reference MABRY CC, PODOLL E. Above average intelligence in untreated phenylketonuria. J Pediatr. 1963;63:1038–40.CrossRefPubMed MABRY CC, PODOLL E. Above average intelligence in untreated phenylketonuria. J Pediatr. 1963;63:1038–40.CrossRefPubMed
19.
go back to reference Culley PD. Another population of phenylketonuria? Studies on atypical phenylketonurics. Dev Med Child Neurol. 1969;11(6):718–29.PubMed Culley PD. Another population of phenylketonuria? Studies on atypical phenylketonurics. Dev Med Child Neurol. 1969;11(6):718–29.PubMed
20.
go back to reference ARMSTRONG MD, CARLISLE JW, LOW NL. Phenylketonuria; two unusual cases. Lancet. 1956;271(6949):917–8.PubMed ARMSTRONG MD, CARLISLE JW, LOW NL. Phenylketonuria; two unusual cases. Lancet. 1956;271(6949):917–8.PubMed
21.
22.
go back to reference Weglage J, Moller HE, Wiedermann D, Cipcic-Schmidt S, Zschocke J, Ullrich K. In vivo NMR spectroscopy in patients with phenylketonuria: clinical significance of interindividual differences in brain phenylalanine concentrations. J Inherit Metab Dis. 1998;21(1):81–2.CrossRefPubMed Weglage J, Moller HE, Wiedermann D, Cipcic-Schmidt S, Zschocke J, Ullrich K. In vivo NMR spectroscopy in patients with phenylketonuria: clinical significance of interindividual differences in brain phenylalanine concentrations. J Inherit Metab Dis. 1998;21(1):81–2.CrossRefPubMed
23.
go back to reference Moller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab. 1998;18(11):1184–91.CrossRefPubMed Moller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab. 1998;18(11):1184–91.CrossRefPubMed
24.
go back to reference Jervis GA. The clinical picture. In: Lyman FL, editor. Phenylketonuria; 1963. p. 52–61. Jervis GA. The clinical picture. In: Lyman FL, editor. Phenylketonuria; 1963. p. 52–61.
25.
go back to reference KNOX WE. An evaluation of the treatment of phenylketonuria with diets low in phenylalanine. Pediatrics. 1960;26:1–11.PubMed KNOX WE. An evaluation of the treatment of phenylketonuria with diets low in phenylalanine. Pediatrics. 1960;26:1–11.PubMed
26.
go back to reference Murphy GH, Johnson SM, Amos A, Weetch E, Hoskin R, Fitzgerald B, Lilburn M, Robertson L, Lee P. Adults with untreated phenylketonuria: out of sight, out of mind. Br J Psychiatry. 2008;193(6):501–2.CrossRefPubMedPubMedCentral Murphy GH, Johnson SM, Amos A, Weetch E, Hoskin R, Fitzgerald B, Lilburn M, Robertson L, Lee P. Adults with untreated phenylketonuria: out of sight, out of mind. Br J Psychiatry. 2008;193(6):501–2.CrossRefPubMedPubMedCentral
27.
go back to reference Hanley WB. Finding the fertile woman with phenylketonuria. Eur J Obstet Gynecol Reprod Biol. 2008;137(2):131–5.CrossRefPubMed Hanley WB. Finding the fertile woman with phenylketonuria. Eur J Obstet Gynecol Reprod Biol. 2008;137(2):131–5.CrossRefPubMed
28.
go back to reference Moller LB, Paulsen M, Koch R, Moats R, Guldberg P, Guttler F. Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex. Mol Genet Metab. 2005;86(Suppl 1):S119–23.CrossRefPubMed Moller LB, Paulsen M, Koch R, Moats R, Guldberg P, Guttler F. Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex. Mol Genet Metab. 2005;86(Suppl 1):S119–23.CrossRefPubMed
Metadata
Title
Can untreated PKU patients escape from intellectual disability? A systematic review
Authors
Danique van Vliet
Annemiek M. J. van Wegberg
Kirsten Ahring
Miroslaw Bik-Multanowski
Nenad Blau
Fatma D. Bulut
Kari Casas
Bozena Didycz
Maja Djordjevic
Antonio Federico
François Feillet
Maria Gizewska
Gwendolyn Gramer
Jozef L. Hertecant
Carla E. M. Hollak
Jens V. Jørgensen
Daniela Karall
Yuval Landau
Vincenzo Leuzzi
Per Mathisen
Kathryn Moseley
Neslihan Ö. Mungan
Francesca Nardecchia
Katrin Õunap
Kimberly K. Powell
Radha Ramachandran
Frank Rutsch
Aria Setoodeh
Maja Stojiljkovic
Fritz K. Trefz
Natalia Usurelu
Callum Wilson
Clara D. van Karnebeek
William B. Hanley
Francjan J. van Spronsen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0890-7

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue